1,398 results on '"Rousselot, Philippe"'
Search Results
2. Comets $^{12}$CO$^+$ and $^{13}$CO$^+$ fluorescence models for measuring the $^{12}$C/$^{13}$C isotopic ratio in CO$^+$
- Author
-
Rousselot, Philippe, Jehin, Emmanuel, Hutsemékers, Damien, Opitom, Cyrielle, Manfroid, Jean, and Hardy, Pierre
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
Context: CO is an abundant species in comets, creating CO$^+$ ion with emission lines that can be observed in the optical spectral range. A good modeling of its fluorescence spectrum is important for a better measurement of the CO$^+$ abundance. Such a species, if abundant enough, can also be used to measure the $^{12}$C/$^{13}$C isotopic ratio. Aims: This study uses the opportunity of a high CO content observed in the comet C/2016 R2 (PanSTARRS), that created bright CO$^{+}$ emission lines in the optical range, to build and test a new fluorescence model of this species and to measure for the first time the $^{12}$C/$^{13}$C isotopic ratio in this chemical species with ground-based observations. Methods: Thanks to laboratory data and theoretical works available in the scientific literature we developed a new fluorescence model both for $^{12}$CO$^+$ and $^{13}$CO$^+$ ions. The $^{13}$CO$^+$ model can be used for coadding faint emission lines and obtain a sufficient signal-to-noise ratio to detect this isotopologue. Results: Our fluorescence model provides a good modeling of the $^{12}$CO$^+$ emission lines, allowing to publish revised fluorescence efficiencies. Based on similar transition probabilities for $^{12}$CO$^+$ and $^{13}$CO$^+$ we derive a $^{12}$C/$^{13}$C isotopic ratio of 73$\pm$20 for CO$^+$ in comet C/2016 R2. This value is in agreement with the solar system ratio of 89$\pm$2 within the error bars, making the possibility that this comet was an interstellar object unlikely., Comment: 11 pages, 8 figures
- Published
- 2023
3. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
- Author
-
Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel, Hochhaus, Andreas, Lipton, Jeffrey, Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, Kantarjian, Hagop, and Shah, Neil Pravin
- Subjects
Humans ,Drug Resistance ,Neoplasm ,Leukemia ,Myeloid ,Chronic-Phase ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Imidazoles ,Pyridazines ,Fusion Proteins ,bcr-abl ,Protein Kinase Inhibitors ,Antineoplastic Agents - Abstract
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial. However, cardiovascular toxicities, including arterial occlusive events (AOEs), have emerged as treatment-related AEs within this class of TKIs. The OPTIC trial evaluated the efficacy and safety of ponatinib using a novel, response-based, dose-reduction strategy in patients with CP-CML whose disease is resistant to ≥2 TKIs or who harbor T315I. To assess the dose-response relationship and the effect on the safety of ponatinib, we examined the outcomes of patients with CP-CML enrolled in PACE and OPTIC who received 45 mg/day of ponatinib. A propensity score analysis was used to evaluate AOEs across both trials. Survival rates and median time to achieve ≤1% BCR::ABL1IS in OPTIC were similar or better than in PACE. The outcomes of patients with T315I mutations were robust in both trials. Patients in OPTIC had a lower exposure-adjusted incidence of AOEs compared with those in PACE. This analysis demonstrates that response-based dosing for ponatinib improves treatment tolerance and mitigates cardiovascular risk.
- Published
- 2024
4. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Author
-
Chevallier, Patrice, Leguay, Thibaut, Delord, Marc, Salek, Cyril, Kim, Rathana, Huguet, Françoise, Hicheri, Yosr, Wartiovaara-Kautto, Ulla, Raffoux, Emmanuel, Cluzeau, Thomas, Balsat, Marie, Roth-Guepin, Gabrielle, Tavernier, Emmanuelle, Lepretre, Stephane, Bilger, Karin, Bergugnat, Hugo, Berceanu, Ana, Alexis, Magda, Doubek, Michael, Brissot, Eolia, Hunault-Berger, Mathilde, Lebon, Delphine, Turlure, Pascal, Chantepie, Sylvain, Belhabri, Amine, Wickenhauser, Stefan, Bastie, Jean-Noel, Cacheux, Victoria, Himberlin, Chantal, Banos, Anne, Gardin, Claude, Bonnet, Sarah, Plantier, Isabelle, Pica, Gian Matteo, Escoffre-Barbe, Martine, Boissel, Nicolas, Dombret, Herve, Clappier, Emmanuelle, Rousselot, Philippe, Lebon, Delphine, Charbonnier, Amandine, Assouan, Deborah, Hubert, Amandine, Quint, Marine, Kossi, Fulvia Guenbem, Deruche, Elodie, Hunault, Mathilde, Marie, Céline, Banos, Anne, Robin, Jean-Baptiste, Gay, Julie, Capdupuy, Claudie, Labarrere, Sévérine, Vincent, Edith, Simonet-Boissard, Marion, BeRceanu, Ana, Larosa, Fabrice, Desbrosses, Yohan, Boiteux, Guillaume, Dufour, Vinciane, Tissot, Elise, Braun, Thorsten, Gardin, Pr Claude, Vidal, Valérie, Edouart, Geoffrey, Chantepie, Sylvain, Vilque, Jean-Pierre, Johnson Ansah, Hyacinthe, Lebouvier, Angélique, Zapalovicz, Marie Charlotte, Renault, Léa, Gian Matteo, Pica, Courouau, Alix, Prieur, Fabienne, Dupre, Charlene, Cacheux, Victoria, De Renzis, Benoit, Chaleteix, Carine, Fayard, Amandine, Roy, Gwendoline, Bastie, Jean-Noël, Caillot, Denis, Devaux, Laetitia, Chevallier, Patrice, Lebourgeois, Amandine, Bonnet, Antoine, Peterlin, Pierre, Lok, Anne, Guilllaume, Thierry, Fontaine, Alexis Morice, Turlure, Pascal, Touati, Mohamed, Kennel, Céline, Dmytruck, Natalya, Abraham, Julie, Jaccard, Arnaud, Remenieras, Liliane, Girault, Stéphane, Gourin, Marie Pierre, Penot, Amélie, Moreau, Stéphane, Philipon, Céline, Roche, Delphine, Belhabri, Amine, Gilis, Lila, Virelizier, Nicolas, Michalet, Anne-Sophie, Monfray, Jérémy, Balsat, Marie, Thomas, Xavier, Praire, Aline, Guepin, Gabrielle Roth, Bonmati, Caroline, Moulin, Charline, Jacquet, Caroline, Carpodomi, Anne, Bouillet, Hélène, Carpentier, Odile, Montero, Mélanie, Pires, Aude, Gastaud, Lauris, Gama, Anastasia, Coelle, Céline, Karmout, Sonia, Cluzeau, Thomas, Loschi, Michael, Lechardeur, Jessica, Chokri, Hatroubi, Broussot, Loic, Wickenhauser, Stefan, Waulthier, Agathe, Jourdan, Eric, Scherman, Elodie, Umuhire, Diane, Damiano, Maria Alessandra, Hicheri, Yors, Saillard, Colombe, DʼIncan, Evelyne, Hospital, Marie-Anne, LʼAttention, Jean Laurent, Rabah, Mme Nassima, Cesari, Laura Castillo, Gehlkopf, Eve, Vincent, Laure, Navarro, Robert, Quittet, Philippe, Fegueux, Nathalie, Ceballos, Patrice, Marin, Fanny Baguet, Sabadash, Véra, Alexis, Magda, Ochmann, Marlène, Laboure, Nina Akakelyan, Bembrahmi, Omar, Michel, Olivier, Ouahrawi, Brahim, Brissot, Eolia, Legrand, Olivier, Vekhoff, Anne, Isnard, Françoise, Sa, Sara E., Dombret, Hervé, Raffoux, Emmanuel, Lenguine, Etienne, Rabian, Florence, Lebras, Karine Celli, Fauvaux, Catherine, Leguay, Thibaut, Gros, François-Xavier, Debus, Cazaubiel, Titouan, Melot, Cyril, Dematteis, Valentin, Messina, Antonella, Himberlin, Chantal, Le, Quoc-Hung, Maggi, Lucia, Barre, Martine Escoffre, Moignet, Aline, De Guibert, Sophie, Bernard, Marc, Decaux, Olivier, de la Chapelle, Thierry Lamy, Nimubona, Stanislas, Kadende, Mme Erica, Flavigny, Aloyse, Plantier, Isabelle, Detourmignies, Laurence, Wemeau, Mathieu, Dervite, Isabelle, Dernivoix, Kathy, Camille, Mme, Denizart, Ingrid, Lepretre, Stéphane, Stamatoullas-Bastard, Aspasia, Fontoura, Marie-Laure, Jardin, Fabrice, Menard, Anne-Lise, Camus, Vincent, Lanic, Helene, Contentin, Nathalie, Cardinael, Nathalie, Lemasle-Hue, Emilie, Alani, Mustafa, Lebreton, Pierre, Atia, Youcef, Bilger, Karin, Ledoux, Marie-Pierre, Sonntag, Cécile, Collin, Camille, Tavernier, Emmanuelle, Guyotat, Denis, Soglu, Gilbert, Le Jeune, Caroline, Cornillon, Jérôme, Durieux, Coralie, Lavoué, Céline, Miler, Dorante, Huguet, Françoise, Tavitian, Suzanne, Soldan, Justine, Rousselot, Philippe, Rigaudeau, Sophie, Philippe, Laure, Lambert, Juliette, Besson, Caroline, Cabannes, Aurélie, Longval, Thomas, Taksin, Anne-Laure, Bah, Mariama, BeulayGue, Anaïs, Doubek, Michael, Folber, Frantisek, Hrabovsky, Stepan, Brzonova, Jana, Vejsadova, Hana, Salek, Cyril, Novotova, Elena, Mertova, Jolana, Brzonova, Jana, Vejsadova, Hana, Wartiovaara-Kautto, Ulla, Salonen, Minna, and Vaalas, Saara
- Published
- 2024
- Full Text
- View/download PDF
5. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
- Author
-
Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel J., Hochhaus, Andreas, Lipton, Jeffrey H., Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Kantarjian, Hagop
- Published
- 2024
- Full Text
- View/download PDF
6. The N$_2$ Production Rate in Comet C/2016 R2 (PanSTARRS)
- Author
-
Anderson, Sarah E., Rousselot, Philippe, Noyelles, Benoît, Opitom, Cyrielle, Jehin, Emmanuel, Hutsemeker, Damien, and Manfroid, Jean
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
Observations of comet C/2016 R2 (PanSTARRS) have revealed exceptionally bright emission bands of N$_2^+$, the strongest ever observed in a comet spectrum. Alternatively, it appears to be poor in CN compared to other comets, and remarkably depleted in H$_2$O. Here we quantify the N$_2$ production rate from N$_2^+$ emission lines using the Haser model. We derived effective parent and daughter scalelengths for N2 producing N2+. This is the first direct measurement of such parameters. Using a revised fluorescence efficiency for N2+, the resulting production rate of molecular nitrogen is inferred to be Q(N$_2$) ~ 1 $\times 10^{28}$ molecules.s-1 on average for 11, 12, and 13 Feb. 2018, the highest for any known comet. Based on a CO production rate of Q(CO) ~ 1.1 $\times 10^{29}$ molecules.s-1, we find Q(N$-2$)/Q(CO)~0.09, which is consistent with the N$_2^+$/CO$^+$ ratio derived from the observed intensities of N$_2^+$ and CO$^+$ emission lines. We also measure significant variations in this production rate between our three observing nights, with Q(N$_2$) varying by plus or minus 20% according to the average value, Comment: 8 pages, 6 figures
- Published
- 2022
- Full Text
- View/download PDF
7. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
- Author
-
Simonin, Mathieu, Vasseur, Loïc, Lengliné, Etienne, Lhermitte, Ludovic, Cabannes-Hamy, Aurélie, Balsat, Marie, Schmidt, Aline, Dourthe, Marie-Emilie, Touzart, Aurore, Graux, Carlos, Grardel, Nathalie, Cayuela, Jean-Michel, Arnoux, Isabelle, Gandemer, Virginie, Huguet, Françoise, Ducassou, Stéphane, Lhéritier, Véronique, Chalandon, Yves, Ifrah, Norbert, Dombret, Hervé, Macintyre, Elizabeth, Petit, Arnaud, Rousselot, Philippe, Lambert, Jérôme, Baruchel, André, Boissel, Nicolas, and Asnafi, Vahid
- Published
- 2024
- Full Text
- View/download PDF
8. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
- Author
-
Chalandon, Yves, Rousselot, Philippe, Chevret, Sylvie, Cayuela, Jean-Michel, Kim, Rathana, Huguet, Françoise, Chevallier, Patrice, Graux, Carlos, Thiebaut-Bertrand, Anne, Chantepie, Sylvain, Thomas, Xavier, Vincent, Laure, Berthon, Céline, Hicheri, Yosr, Raffoux, Emmanuel, Escoffre-Barbe, Martine, Plantier, Isabelle, Joris, Magalie, Turlure, Pascal, Pasquier, Florence, Belhabri, Amine, Guepin, Gabrielle Roth, Blum, Sabine, Gregor, Michael, Lafage-Pochitaloff, Marina, Quessada, Julie, Lhéritier, Véronique, Clappier, Emmanuelle, Boissel, Nicolas, and Dombret, Hervé
- Published
- 2024
- Full Text
- View/download PDF
9. Interstellar comet 2I/Borisov as seen by MUSE: C$_2$, NH$_2$ and red CN detections
- Author
-
Bannister, Michele T., Opitom, Cyrielle, Fitzsimmons, Alan, Moulane, Youssef, Jehin, Emmanuel, Seligman, Darryl, Rousselot, Philippe, Knight, Matthew M., Marsset, Michael, Schwamb, Megan E., Guilbert-Lepoutre, Aurélie, Jorda, Laurent, Vernazza, Pierre, and Benkhaldoun, Zouhair
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We report the clear detection of C$_2$ and of abundant NH$_2$ in the first prominently active interstellar comet, 2I/Borisov. We observed 2I on three nights in November 2019 at optical wavelengths 4800--9300 \AA with the Multi-Unit Spectroscopic Explorer (MUSE) integral-field spectrograph on the ESO/Very Large Telescope. These data, together with observations close in time from both 0.6-m TRAPPIST telescopes, provide constraints on the production rates of species of gas in 2I's coma. From the MUSE detection on all epochs of several bands of the optical emission of the C$_2$ Swan system, a rich emission spectrum of NH$_2$ with many highly visible bands, and the red (1-0) bandhead of CN, together with violet CN detections by TRAPPIST, we infer production rates of $Q$(C$_2$) = $1.1\times10^{24}$ mol s$^{-1}$, $Q$(NH$_2$) = $4.8\times10^{24}$ mol s$^{-1}$ and $Q$(CN) = $(1.8\pm0.2)\times 10^{24}$ mol s$^{-1}$. In late November at 2.03~au, 2I had a production ratio of C$_2$/CN$=0.61$, only barely carbon-chain depleted, in contrast to earlier reports measured further from the Sun of strong carbon-chain depletion. Thus, 2I has shown evolution in its C$_2$ production rate: a parent molecule reservoir has started sublimating. At $Q$(NH$_2$)/$Q$(CN) = 2.7, this second interstellar object is enriched in NH$_2$, relative to the known Solar System sample., Comment: 5 figures. Submitted to AAS Journals
- Published
- 2020
10. BlueMUSE: Project Overview and Science Cases
- Author
-
Richard, Johan, Bacon, Roland, Blaizot, Jérémy, Boissier, Samuel, Boselli, Alessandro, NicolasBouché, Brinchmann, Jarle, Castro, Norberto, Ciesla, Laure, Crowther, Paul, Daddi, Emanuele, Dreizler, Stefan, Duc, Pierre-Alain, Elbaz, David, Epinat, Benoit, Evans, Chris, Fossati, Matteo, Fumagalli, Michele, Garcia, Miriam, Garel, Thibault, Hayes, Matthew, Adamo, Angela, Herrero, Artemio, Hugot, Emmanuel, Humphrey, Andrew, Jablonka, Pascale, Kamann, Sebastian, Kaper, Lex, Kelz, Andreas, Kneib, Jean-Paul, de Koter, Alex, Krajnović, Davor, Kudritzki, Rolf-Peter, Langer, Norbert, Lardo, Carmela, Leclercq, Floriane, Lennon, Danny, Mahler, Guillaume, Martins, Fabrice, Massey, Richard, Mitchell, Peter, Monreal-Ibero, Ana, Najarro, Paco, Opitom, Cyrielle, Papaderos, Polychronis, Péroux, Céline, Revaz, Yves, Roth, Martin M., Rousselot, Philippe, Sander, Andreas, Wagemann, Charlotte Simmonds, Smail, Ian, Swinbank, Anthony Mark, Tramper, Frank, Urrutia, Tanya, Verhamme, Anne, Vink, Jorick, Walsh, Jeremy, Weilbacher, Peter, Wendt, Martin, Wisotzki, Lutz, and Yang, Bin
- Subjects
Astrophysics - Instrumentation and Methods for Astrophysics ,Astrophysics - Cosmology and Nongalactic Astrophysics ,Astrophysics - Astrophysics of Galaxies ,Astrophysics - Solar and Stellar Astrophysics - Abstract
We present the concept of BlueMUSE, a blue-optimised, medium spectral resolution, panoramic integral field spectrograph based on the MUSE concept and proposed for the Very Large Telescope. With an optimised transmission down to 350 nm, a larger FoV (1.4 x 1.4 arcmin$^2$) and a higher spectral resolution compared to MUSE, BlueMUSE will open up a new range of galactic and extragalactic science cases allowed by its specific capabilities, beyond those possible with MUSE. For example a survey of massive stars in our galaxy and the Local Group will increase the known population of massive stars by a factor $>$100, to answer key questions about their evolution. Deep field observations with BlueMUSE will also significantly increase samples of Lyman-alpha emitters, spanning the era of Cosmic Noon. This will revolutionise the study of the distant Universe: allowing the intergalactic medium to be detected unambiguously in emission, enabling the study of the exchange of baryons between galaxies and their surroundings. By 2030, at a time when the focus of most of the new large facilities (ELT, JWST) will be on the infra-red, BlueMUSE will be a unique facility, outperforming any ELT instrument in the Blue/UV. It will have a strong synergy with ELT, JWST as well as ALMA, SKA, Euclid and Athena., Comment: 60 pages, 22 figures, minor updates
- Published
- 2019
11. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition
- Author
-
Courtois, Lucien, Cabannes-Hamy, Aurélie, Kim, Rathana, Delecourt, Marine, Pinton, Antoine, Charbonnier, Guillaume, Feroul, Mélanie, Smith, Charlotte, Tueur, Giulia, Pivert, Cécile, Balducci, Estelle, Simonin, Mathieu, Angel, Laure Hélène, Spicuglia, Salvatore, Boissel, Nicolas, Andrieu, Guillaume P., Asnafi, Vahid, Rousselot, Philippe, and Lhermitte, Ludovic
- Published
- 2023
- Full Text
- View/download PDF
12. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
- Author
-
de Botton, Stéphane, Cluzeau, Thomas, Vigil, Carlos, Cook, Rachel J., Rousselot, Philippe, Rizzieri, David A., Liesveld, Jane L., Fenaux, Pierre, Braun, Thorsten, Banos, Anne, Jurcic, Joseph G., Sekeres, Mikkael A., Savona, Michael R., Roboz, Gail J., Bixby, Dale, Madigan, Kate, Volkert, Angela, Stephens, Kristin, Kang-Fortner, Qing, Baker, Kristen, Paul, Sofia, McKeown, Michael, Carulli, John, Eaton, Matthew, Hodgson, Graeme, Fiore, Christopher, Kelly, Michael J., Roth, David A., and Stein, Eytan M.
- Published
- 2023
- Full Text
- View/download PDF
13. UV exploration of the solar system
- Author
-
Chaufray, Jean-Yves, Lamy, Laurent, Rousselot, Philippe, and Barthelemy, Mathieu
- Published
- 2022
- Full Text
- View/download PDF
14. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
- Author
-
Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, and Deininger, Michael W.
- Published
- 2022
- Full Text
- View/download PDF
15. OSSOS. VII. 800+ trans-Neptunian objects - the complete data release
- Author
-
Bannister, Michele T., Gladman, Brett J., Kavelaars, J. J., Petit, Jean-Marc, Volk, Kathryn, Chen, Ying-Tung, Alexandersen, Mike, Gwyn, Stephen D. J., Schwamb, Megan E., Ashton, Edward, Benecchi, Susan D., Cabral, Nahuel, Dawson, Rebekah I., Delsanti, Audrey, Fraser, Wesley C., Granvik, Mikael, Greenstreet, Sarah, Guilbert-Lepoutre, Aurélie, Ip, Wing-Huen, Jakubik, Marian, Jones, R. Lynne, Kaib, Nathan A., Lacerda, Pedro, Van Laerhoven, Christa, Lawler, Samantha, Lehner, Matthew J., Lin, Hsing Wen, Lykawka, Patryk Sofia, Marsset, Michaël, Murray-Clay, Ruth, Pike, Rosemary E., Rousselot, Philippe, Shankman, Cory, Thirouin, Audrey, Vernazza, Pierre, and Wang, Shiang-Yu
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
The Outer Solar System Origins Survey (OSSOS), a wide-field imaging program in 2013-2017 with the Canada-France-Hawaii Telescope, surveyed 155 deg$^{2}$ of sky to depths of $m_r = 24.1$-25.2. We present 838 outer Solar System discoveries that are entirely free of ephemeris bias. This increases the inventory of trans-Neptunian objects (TNOs) with accurately known orbits by nearly 50%. Each minor planet has 20-60 Gaia/Pan-STARRS-calibrated astrometric measurements made over 2-5 oppositions, which allows accurate classification of their orbits within the trans-Neptunian dynamical populations. The populations orbiting in mean-motion resonance with Neptune are key to understanding Neptune's early migration. Our 313 resonant TNOs, including 132 plutinos, triple the available characterized sample and include new occupancy of distant resonances out to semi-major axis $a \sim 130$ au. OSSOS doubles the known population of the non-resonant Kuiper belt, providing 436 TNOs in this region, all with exceptionally high-quality orbits of $a$ uncertainty $\sigma_{a} \leq 0.1\%$; they show the belt exists from $a \gtrsim 37$ au, with a lower perihelion bound of $35$ au. We confirm the presence of a concentrated low-inclination $a\simeq 44$ au "kernel" population and a dynamically cold population extending beyond the 2:1 resonance. We finely quantify the survey's observational biases. Our survey simulator provides a straightforward way to impose these biases on models of the trans-Neptunian orbit distributions, allowing statistical comparison to the discoveries. The OSSOS TNOs, unprecedented in their orbital precision for the size of the sample, are ideal for testing concepts of the history of giant planet migration in the Solar System., Comment: Invited paper, special issue Data: Insights and Challenges in a Time of Abundance. Data tables and example survey simulator are in the supplementary materials (see arXiv source under Downloads > Other formats)
- Published
- 2018
- Full Text
- View/download PDF
16. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
- Author
-
Hughes, Timothy P, Laneuville, Pierre, Rousselot, Philippe, Snyder, David S, Rea, Delphine, Shah, Neil P, Paar, David, Abruzzese, Elisabetta, Hochhaus, Andreas, Lipton, Jeffrey H, and Cortes, Jorge E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Orphan Drug ,Pediatric Research Initiative ,Pediatric ,Clinical Trials and Supportive Activities ,Hematology ,Childhood Leukemia ,Pediatric Cancer ,Rare Diseases ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Dasatinib ,Disease-Free Survival ,Female ,Humans ,Incidence ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Male ,Middle Aged ,Pleural Effusion ,Malignant ,Risk Factors ,Survival Rate ,Cardiorespiratory Medicine and Haematology ,Immunology ,Cardiovascular medicine and haematology - Abstract
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or resistance. While generally well tolerated, dasatinib has been associated with a higher risk for pleural effusions. Frequency, risk factors, and outcomes associated with pleural effusion were assessed in two phase 3 trials (DASISION and 034/Dose-optimization) and a pooled population of 11 trials that evaluated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib (including DASISION and 034/Dose-optimization). In this largest assessment of patients across the dasatinib clinical trial program (N=2712), pleural effusion developed in 6-9% of patients at risk annually in DASISION, and in 5-15% of patients at risk annually in 034/Dose-optimization. With a minimum follow up of 5 and 7 years, drug-related pleural effusion occurred in 28% of patients in DASISION and in 33% of patients in 034/Dose-optimization, respectively. A significant risk factor identified for developing pleural effusion by a multivariate analysis was age. We found that overall responses to dasatinib, progression-free survival, and overall survival were similar in patients who developed pleural effusion and in patients who did not. clinicaltrials.gov identifier 00481247; 00123474.
- Published
- 2019
17. Ubi solitudinem inveniunt, pacem appellant: French Colonial Empire as Rome’s Mirror
- Author
-
Rousselot, Philippe, primary
- Published
- 2022
- Full Text
- View/download PDF
18. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL
- Author
-
Passet, Marie, Kim, Rathana, Gachet, Stéphanie, Sigaux, François, Chaumeil, Julie, Galland, Ava, Sexton, Thomas, Quentin, Samuel, Hernandez, Lucie, Larcher, Lise, Bergugnat, Hugo, Ye, Tao, Karasu, Nezih, Caye, Aurélie, Heizmann, Beate, Duluc, Isabelle, Chevallier, Patrice, Rousselot, Philippe, Huguet, Françoise, Leguay, Thibaut, Hunault, Mathilde, Pflumio, Françoise, Freund, Jean-Noël, Lobry, Camille, Lhéritier, Véronique, Dombret, Hervé, Domon-Dell, Claire, Soulier, Jean, Boissel, Nicolas, and Clappier, Emmanuelle
- Published
- 2022
- Full Text
- View/download PDF
19. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
- Author
-
Kreitman, Robert, Dearden, Claire, Zinzani, Pier, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas, le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri, Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia, Saglio, Giuseppe, Roboz, Gail, Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis
- Subjects
Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Bacterial Toxins ,Drug Resistance ,Neoplasm ,Exotoxins ,Female ,Follow-Up Studies ,Humans ,Leukemia ,Hairy Cell ,Male ,Middle Aged ,Neoplasm Recurrence ,Local ,Prognosis ,Remission Induction ,Salvage Therapy ,Survival Rate - Abstract
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.
- Published
- 2018
20. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- Author
-
Cortes, Jorge, Perl, Alexander E, Döhner, Hartmut, Kantarjian, Hagop, Martinelli, Giovanni, Kovacsovics, Tibor, Rousselot, Philippe, Steffen, Björn, Dombret, Hervé, Estey, Elihu, Strickland, Stephen, Altman, Jessica K, Baldus, Claudia D, Burnett, Alan, Krämer, Alwin, Russell, Nigel, Shah, Neil P, Smith, Catherine C, Wang, Eunice S, Ifrah, Norbert, Gammon, Guy, Trone, Denise, Lazzaretto, Deborah, and Levis, Mark
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Hematology ,Cancer ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Administration ,Oral ,Adult ,Aged ,Benzothiazoles ,Canada ,Disease-Free Survival ,Dose-Response Relationship ,Drug ,Drug Administration Schedule ,Europe ,Female ,Humans ,Internationality ,Leukemia ,Myeloid ,Acute ,Male ,Maximum Tolerated Dose ,Middle Aged ,Neoplasm Recurrence ,Local ,Phenylurea Compounds ,Prognosis ,Survival Rate ,Treatment Outcome ,United States ,Young Adult ,fms-Like Tyrosine Kinase 3 ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundOld age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia.MethodsWe did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission + complete remission with incomplete platelet recovery + complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed.FindingsBetween Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [
- Published
- 2018
21. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
- Author
-
Deininger, Michael, primary, Apperley, Jane, additional, Arthur, Christopher Kevin, additional, Chuah, Charles, additional, Hochhaus, Andreas, additional, de Lavallade, Hugues, additional, Lipton, Jeffrey Howard, additional, Lomaia, Elza, additional, McCloskey, James K., additional, Maness, Lori J., additional, Mauro, Michael J., additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rosti, Gianantonio, additional, Rousselot, Philippe, additional, Undurraga Sutton, Maria, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, Kantarjian, Hagop M., additional, and Cortes, Jorge E., additional
- Published
- 2024
- Full Text
- View/download PDF
22. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
- Author
-
Jabbour, Elias, primary, Kantarjian, Hagop M., additional, Aldoss, Ibrahim, additional, Montesinos, Pau, additional, Leonard, Jessica Taft, additional, Gomez-Almaguer, David, additional, Baer, Maria R., additional, Gambacorti-Passerini, Carlo, additional, McCloskey, James K., additional, Minami, Yosuke, additional, Papayannidis, Cristina, additional, Rousselot, Philippe, additional, Vachhani, Pankit, additional, Wang, Eunice S., additional, Yang, Lin, additional, Hennessy, Meliessa, additional, Vorog, Alexander, additional, Patel, Niti, additional, and Ribera-Santasusana, Jose-Maria, additional
- Published
- 2024
- Full Text
- View/download PDF
23. The stepbrothers of ABLSON have their own sensitivity
- Author
-
Rousselot, Philippe, primary
- Published
- 2024
- Full Text
- View/download PDF
24. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- Author
-
Jabbour, Elias, primary, Kantarjian, Hagop M., additional, Aldoss, Ibrahim, additional, Montesinos, Pau, additional, Leonard, Jessica T., additional, Gómez-Almaguer, David, additional, Baer, Maria R., additional, Gambacorti-Passerini, Carlo, additional, McCloskey, James, additional, Minami, Yosuke, additional, Papayannidis, Cristina, additional, Rocha, Vanderson, additional, Rousselot, Philippe, additional, Vachhani, Pankit, additional, Wang, Eunice S., additional, Wang, Bingxia, additional, Hennessy, Meliessa, additional, Vorog, Alexander, additional, Patel, Niti, additional, Yeh, Tammie, additional, and Ribera, Jose-Maria, additional
- Published
- 2024
- Full Text
- View/download PDF
25. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
- Author
-
Lambert, Juliette, Lambert, Jerome, Thomas, Xavier, Marceau-Renaut, Alice, Micol, Jean-Baptiste, Renneville, Aline, Clappier, Emmanuelle, Hayette, Sandrine, Récher, Christian, Raffoux, Emmanuel, Pigneux, Arnaud, Berthon, Celine, Terré, Christine, Celli-Lebras, Karine, Castaigne, Sylvie, Boissel, Nicolas, Rousselot, Philippe, Preudhomme, Claude, Dombret, Hervé, and Duployez, Nicolas
- Published
- 2021
- Full Text
- View/download PDF
26. KMT2A-ARHGEF12, a therapy related fusion with poor prognosis
- Author
-
Assaf, Nada, Liévin, Raphael, Merabet, Fatiha, Raggueneau, Victoria, Osman, Jenifer, Kim, Rathana, Garnache, Francine, D’Angiò, Mariella, Larghero, Patrizia, Meyer, Claus, Marschalek, Rolf, Rousselot, Philippe, and Terré, Christine
- Published
- 2021
- Full Text
- View/download PDF
27. The perihelion activity of comet 67P/Churyumov-Gerasimenko as seen by robotic telescopes
- Author
-
Snodgrass, Colin, Opitom, Cyrielle, de Val-Borro, Miguel, Jehin, Emmanuel, Manfroid, Jean, Lister, Tim, Marchant, Jon, Jones, Geraint H., Fitzsimmons, Alan, Steele, Iain A., Smith, Robert J., Jermak, Helen, Granzer, Thomas, Meech, Karen J., Rousselot, Philippe, and Levasseur-Regourd, Anny-Chantal
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
Around the time of its perihelion passage the observability of 67P/Churyumov-Gerasimenko from Earth was limited to very short windows each morning from any given site, due to the low solar elongation of the comet. The peak in the comet's activity was therefore difficult to observe with conventionally scheduled telescopes, but was possible where service/queue scheduled mode was possible, and with robotic telescopes. We describe the robotic observations that allowed us to measure the total activity of the comet around perihelion, via photometry (dust) and spectroscopy (gas), and compare these results with the measurements at this time by Rosetta's instruments. The peak of activity occurred approximately two weeks after perihelion. The total brightness (dust) largely followed the predictions from Snodgrass et al. 2013, with no significant change in total activity levels from previous apparitions. The CN gas production rate matched previous orbits near perihelion, but appeared to be relatively low later in the year., Comment: To appear in special issue of MNRAS "The ESLAB 50 Symposium - spacecraft at comets from 1P/Halley to 67P/Churyumov-Gerasimenko"
- Published
- 2016
- Full Text
- View/download PDF
28. OSSOS: IV. Discovery of a dwarf planet candidate in the 9:2 resonance with Neptune
- Author
-
Bannister, Michele T., Alexandersen, Mike, Benecchi, Susan D., Chen, Ying-Tung, Delsanti, Audrey, Fraser, Wesley C., Gladman, Brett J., Granvik, Mikael, Grundy, Will M., Guilbert-Lepoutre, Aurelie, Gwyn, Stephen D. J., Ip, Wing-Huen, Jakubik, Marian, Jones, R. Lynne, Kaib, Nathan, Kavelaars, J. J., Lacerda, Pedro, Lawler, Samantha, Lehner, Matthew J., Lin, Hsing Wen, Lykawka, Patryk Sofia, Marsset, Michael, Murray-Clay, Ruth, Noll, Keith S., Parker, Alex, Petit, Jean-Marc, Pike, Rosemary E., Rousselot, Philippe, Schwamb, Megan E., Shankman, Cory, Veres, Peter, Vernazza, Pierre, Volk, Kathryn, Wang, Shiang-Yu, and Weryk, Robert
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We report the discovery and orbit of a new dwarf planet candidate, 2015 RR$_{245}$, by the Outer Solar System Origins Survey (OSSOS). 2015 RR$_{245}$'s orbit is eccentric ($e=0.586$), with a semi-major axis near 82 au, yielding a perihelion distance of 34 au. 2015 RR$_{245}$ has $g-r = 0.59 \pm 0.11$ and absolute magnitude $H_{r} = 3.6 \pm 0.1$; for an assumed albedo of $p_V = 12$% the object has a diameter of $\sim670$ km. Based on astrometric measurements from OSSOS and Pan-STARRS1, we find that 2015 RR$_{245}$ is securely trapped on ten-Myr timescales in the 9:2 mean-motion resonance with Neptune. It is the first TNO identified in this resonance. On hundred-Myr timescales, particles in 2015 RR$_{245}$-like orbits depart and sometimes return to the resonance, indicating that 2015 RR$_{245}$ likely forms part of the long-lived metastable population of distant TNOs that drift between resonance sticking and actively scattering via gravitational encounters with Neptune. The discovery of a 9:2 TNO stresses the role of resonances in the long-term evolution of objects in the scattering disk, and reinforces the view that distant resonances are heavily populated in the current Solar System. This object further motivates detailed modelling of the transient sticking population., Comment: Accepted to AJ
- Published
- 2016
- Full Text
- View/download PDF
29. Cicéron face aux dictateurs, 1920–1945
- Author
-
Rousselot, Philippe, primary
- Published
- 2022
- Full Text
- View/download PDF
30. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia : Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
- Author
-
Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, Saussele, Susanne, Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, and Saussele, Susanne
- Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
- Published
- 2024
- Full Text
- View/download PDF
31. The Outer Solar System Origins Survey: I. Design and First-Quarter Discoveries
- Author
-
Bannister, Michele T., Kavelaars, J. J., Petit, Jean-Marc, Gladman, Brett J., Gwyn, Stephen D. J., Chen, Ying-Tung, Volk, Kathryn, Alexandersen, Mike, Benecchi, Susan, Delsanti, Audrey, Fraser, Wesley, Granvik, Mikael, Grundy, Will M., Guilbert-Lepoutre, Aurelie, Hestroffer, Daniel, Ip, Wing-Huen, Jakubik, Marian, Jones, Lynne, Kaib, Nathan, Kavelaars, Catherine F., Lacerda, Pedro, Lawler, Samantha, Lehner, Matthew J., Lin, Hsing Wen, Lister, Tim, Lykawka, Patryk Sofia, Monty, Stephanie, Marsset, Michael, Murray-Clay, Ruth, Noll, Keith, Parker, Alex, Pike, Rosemary E., Rousselot, Philippe, Rusk, David, Schwamb, Megan E., Shankman, Cory, Sicardy, Bruno, Vernazza, Pierre, and Wang, Shiang-Yu
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We report the discovery, tracking and detection circumstances for 85 trans-Neptunian objects (TNOs) from the first 42 deg$^{2}$ of the Outer Solar System Origins Survey (OSSOS). This ongoing $r$-band Solar System survey uses the 0.9 deg$^{2}$ field-of-view MegaPrime camera on the 3.6 m Canada-France-Hawaii Telescope. Our orbital elements for these TNOs are precise to a fractional semi-major axis uncertainty $<0.1\%$. We achieve this precision in just two oppositions, as compared to the normal 3-5 oppositions, via a dense observing cadence and innovative astrometric technique. These discoveries are free of ephemeris bias, a first for large trans-Neptunian surveys. We also provide the necessary information to enable models of TNO orbital distributions to be tested against our TNO sample. We confirm the existence of a cold "kernel" of objects within the main cold classical Kuiper belt, and infer the existence of an extension of the "stirred" cold classical Kuiper belt to at least several AU beyond the 2:1 mean motion resonance with Neptune. We find that the population model of Petit et al. (2011) remains a plausible representation of the Kuiper belt. The full survey, to be completed in 2017, will provide an exquisitely characterized sample of important resonant TNO populations, ideal for testing models of giant planet migration during the early history of the Solar System., Comment: Accepted to AJ, 27 April 2016. 59 pp
- Published
- 2015
- Full Text
- View/download PDF
32. Methane clathrates in the Solar System
- Author
-
Mousis, Olivier, Chassefière, Eric, Holm, Nils G., Bouquet, Alexis, Waite, Jack Hunter, Geppert, Wolf Dietrich, Picaud, Sylvain, Aikawa, Yuri, Ali-Dib, Mohamad, Charlou, Jean-Luc, and Rousselot, Philippe
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We review the reservoirs of methane clathrates that may exist in the different bodies of the Solar System. Methane was formed in the interstellar medium prior to having been embedded in the protosolar nebula gas phase. This molecule was subsequently trapped in clathrates that formed from crystalline water ice during the cooling of the disk and incorporated in this form in the building blocks of comets, icy bodies, and giant planets. Methane clathrates may play an important role in the evolution of planetary atmospheres. On Earth, the production of methane in clathrates is essentially biological, and these compounds are mostly found in permafrost regions or in the sediments of continental shelves. On Mars, methane would more likely derive from hydrothermal reactions with olivine-rich material. If they do exist, martian methane clathrates would be stable only at depth in the cryosphere and sporadically release some methane into the atmosphere via mechanisms that remain to be determined.
- Published
- 2015
- Full Text
- View/download PDF
33. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study.
- Author
-
Kim, Rathana, Chalandon, Yves, Rousselot, Philippe, Cayuela, Jean-Michel, Huguet, Françoise, Balsat, Marie, Passet, Marie, Chevallier, Patrice, Hicheri, Yosr, Raffoux, Emmanuel, Leguay, Thibaut, Chantepie, Sylvain, Maury, Sébastien, Hayette, Sandrine, Solly, Françoise, Braun, Thorsten, De Prijck, Bernard, Cacheux, Victoria, Salanoubat, Celia, and Farnault, Laure
- Published
- 2024
- Full Text
- View/download PDF
34. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission
- Author
-
Rousselot, Philippe, Loiseau, Clémence, Delord, Marc, Cayuela, Jean Michel, and Spentchian, Marc
- Published
- 2020
- Full Text
- View/download PDF
35. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
- Author
-
Gökbuget, Nicola, primary, Boissel, Nicolas, additional, Chiaretti, Sabina, additional, Dombret, Herve, additional, Doubek, Michael, additional, Fielding, Adele K, additional, Foà, Robin, additional, Giebel, Sebastian, additional, Hoelzer, Dieter, additional, Hunault, Mathilde, additional, Marks, David I, additional, Martinelli, Giovanni, additional, Ottmann, Oliver, additional, Rijneveld, Anita W., additional, Rousselot, Philippe, additional, Ribera, Josep-Maria, additional, and Bassan, Renato, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Old rivals become new friends
- Author
-
Rousselot, Philippe, primary
- Published
- 2024
- Full Text
- View/download PDF
37. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
- Author
-
Gökbuget, Nicola, primary, Boissel, Nicolas, additional, Chiaretti, Sabina, additional, Dombret, Herve, additional, Doubek, Michael, additional, Fielding, Adele K, additional, Foà, Robin, additional, Giebel, Sebastian, additional, Hoelzer, Dieter, additional, Hunault, Mathilde, additional, Marks, David I, additional, Martinelli, Giovanni, additional, Ottmann, Oliver G, additional, Rijneveld, Anita W., additional, Rousselot, Philippe, additional, Ribera, Josep-Maria, additional, and Bassan, Renato, additional
- Published
- 2024
- Full Text
- View/download PDF
38. Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
- Author
-
Pinton, Antoine, primary, Courtois, Lucien, primary, Doublet, Charlotte, primary, Cabannes-Hamy, Aurélie, primary, Andrieu, Guillaume, primary, Smith, Charlotte, primary, Balducci, Estelle, primary, Cieslak, Agata, primary, Touzart, Aurore, primary, Simonin, Mathieu, primary, Lhéritier, Véronique, primary, Huguet, Françoise, primary, Balsat, Marie, primary, Dombret, Hervé, primary, Rousselot, Philippe, primary, Spicuglia, Salvatore, primary, Macintyre, Elizabeth, primary, Boissel, Nicolas, primary, and Asnafi, Vahid, primary
- Published
- 2024
- Full Text
- View/download PDF
39. Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
- Author
-
Pinton, Antoine, primary, Courtois, Lucien, primary, Doublet, Charlotte, primary, Cabannes-Hamy, Aurélie, primary, Andrieu, Guillaume, primary, Smith, Charlotte, primary, Balducci, Estelle, primary, Cieslak, Agata, primary, Touzart, Aurore, primary, Simonin, Mathieu, primary, Lhéritier, Véronique, primary, Huguet, Françoise, primary, Balsat, Marie, primary, Dombret, Hervé, primary, Rousselot, Philippe, primary, Spicuglia, Salvatore, primary, Macintyre, Elizabeth, primary, Boissel, Nicolas, primary, and Asnafi, Vahid, primary
- Published
- 2024
- Full Text
- View/download PDF
40. Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
- Author
-
Pinton, Antoine, primary, Courtois, Lucien, primary, Doublet, Charlotte, primary, Cabannes-Hamy, Aurélie, primary, Andrieu, Guillaume, primary, Smith, Charlotte, primary, Balducci, Estelle, primary, Cieslak, Agata, primary, Touzart, Aurore, primary, Simonin, Mathieu, primary, Lhéritier, Véronique, primary, Huguet, Françoise, primary, Balsat, Marie, primary, Dombret, Hervé, primary, Rousselot, Philippe, primary, Spicuglia, Salvatore, primary, Macintyre, Elizabeth, primary, Boissel, Nicolas, primary, and Asnafi, Vahid, primary
- Published
- 2024
- Full Text
- View/download PDF
41. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
- Author
-
Shah, Neil P, Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E, Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, and Saglio, Giuseppe
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Oncology and Carcinogenesis ,Orphan Drug ,Clinical Research ,Cancer ,Hematology ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Antineoplastic Agents ,Dasatinib ,Disease-Free Survival ,Drug Resistance ,Neoplasm ,Follow-Up Studies ,Humans ,Imatinib Mesylate ,Leukemia ,Myelogenous ,Chronic ,BCR-ABL Positive ,Leukemia ,Myeloid ,Chronic-Phase ,Pancytopenia ,Patient Safety ,Pleural Effusion ,Protein Kinase Inhibitors ,Treatment Outcome ,Cardiorespiratory Medicine and Haematology ,Immunology ,Cardiovascular medicine and haematology - Abstract
Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study. Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI). Patients (n = 670) with imatinib-resistant or -intolerant CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR, PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates were reported in patients who achieved BCR-ABL1 ≤10% at 3 and 6 months. No new safety signals were identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial hypertension remained low (≤3% across all doses). Arterial ischemic events occurred in ≤4% of patients across all doses. These data support the long-term efficacy and well-established safety profile of dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase. Am. J. Hematol. 91:869-874, 2016. © 2016 Wiley Periodicals, Inc.
- Published
- 2016
42. Distant activity of comet C/2002 VQ94 (LINEAR): optical spectrophotometric monitoring between 8.4 and 16.8 au from the Sun
- Author
-
Korsun, Pavlo P., Rousselot, Philippe, Kulyk, Irina V., Afanasiev, Viktor L., and Ivanova, Oleksandra V.
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
Spectrophotometric monitoring of distant comet C/2002 VQ94 (LINEAR) was performed with the 6-m telescope of SAO RAS and with the 2.5-m Nordic Optical Telescope between 2008 and 2013. During this period the comet was on the outbound segment of its orbit, between heliocentric distances of 8.36 au and 16.84 au. Analysis of the spectra revealed the presence of the CO$^+$ and N$_2^+$ emissions in the cometary coma at a distance of 8.36 au from the Sun. This distance is larger than ionic emissions have been detected in any previous objects. Only continuum, with no traces of emissions, was detected in the spectrum obtained in 2009 when the comet was at a distance of 9.86 au. From the spectra obtained in 2008, average column densities of 2.04$\times$10$^9$ mol cm$^{-2}$ for N$_2^+$ and 3.26$\times$10$^{10}$ mol cm$^{-2}$ for CO$^+$ were measured in the cometary coma. The derived values correspond to N$_2^+$/CO$^+$=0.06 within the projected slit. The parameter, which is used as an indicator of cometary activity, was measured as 2000 cm in 2008, and 800 cm in 2009 and 2011. The values correspond to dust production rates between 10-20 kg s$^{-1}$, 4-6 kg s$^{-1}$ and 3-5 kg s$^{-1}$ at 8.36, 9.86, and 13.40 au respectively. There is an obvious correlation between the decrease of the dust production rate of the nucleus and the disappearance of the emissions in the spectrum of C/2002 VQ94 (LINEAR) at heliocentric distances greater than 9 au. The colors and size of the nucleus of C/2002 VQ94 (LINEAR) were estimated from the images obtained during the late stage at a heliocentric distance of 16.84 au, when the activity had probable ceased. The B-V and V-R colors were estimated to be 1.07$\pm$0.05 and 0.54$\pm$0.03 respectively. The effective nucleus radius of 48$\pm$2 km is in agreement with the previously published results, obtained from the observations of the comet during its early inactive stage., Comment: Accepted for publication in Icarus; 19 pages, 4 tables, 9 figures
- Published
- 2014
- Full Text
- View/download PDF
43. The dual origin of the nitrogen deficiency in comets: selective volatile trapping in the nebula and postaccretion radiogenic heating
- Author
-
Mousis, Olivier, Guilbert-Lepoutre, Aurélie, Lunine, Jonathan I., Cochran, Anita L., Waite, J. Hunter, Petit, Jean-Marc, and Rousselot, Philippe
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We propose a scenario that explains the apparent nitrogen deficiency in comets in a way consistent with the fact that the surfaces of Pluto and Triton are dominated by nitrogen-rich ice. We use a statistical thermodynamic model to investigate the composition of the successive multiple guest clathrates that may have formed during the cooling of the primordial nebula from the most abundant volatiles present in the gas phase. These clathrates agglomerated with the other ices (pure condensates or stoichiometric hydrates) and formed the building blocks of comets. We report that molecular nitrogen is a poor clathrate former, when we consider a plausible gas phase composition of the primordial nebula. This implies that its trapping into cometesimals requires a low disk temperature ($\sim$20 K) in order to allow the formation of its pure condensate. We find that it is possible to explain the lack of molecular nitrogen in comets as a consequence of their postformation internal heating engendered by the decay of short-lived radiogenic nuclides. This scenario is found consistent with the presence of nitrogen-rich ice covers on Pluto and Triton. Our model predicts that comets should present xenon-to-water and krypton-to-water ratios close to solar xenon-to-oxygen and krypton-to-oxygen ratios, respectively. In contrast, the argon-to-water ratio is predicted to be depleted by a factor of $\sim$300 in comets compared to solar argon-to-oxygen, as a consequence of poor trapping efficiency and radiogenic heating., Comment: Accepted for publication in The Astrophysical Journal
- Published
- 2012
- Full Text
- View/download PDF
44. The remarkable surface homogeneity of the Dawn mission target (1) Ceres
- Author
-
Carry, Benoit, Vernazza, Pierre, Dumas, Christophe, Merline, William J., Mousis, Olivier, Rousselot, Philippe, Jehin, Emmanuel, Manfroid, Jean, Fulchignoni, Marcello, and Zucconi, Jean-Marc
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
Dwarf-planet (1) Ceres is one of the two targets, along with (4) Vesta, that will be studied by the NASA Dawn spacecraft via imaging, visible and near-infrared spectroscopy, and gamma-ray and neutron spectroscopy. While Ceres' visible and near-infrared disk-integrated spectra have been well characterized, little has been done about quantifying spectral variations over the surface. Any spectral variation would give us insights on the geographical variation of the composition and/or the surface age. The only work so far was that of Rivkin & Volquardsen (2010, Icarus 206, 327) who reported rotationally-resolved spectroscopic (disk-integrated) observations in the 2.2-4.0 {\mu}m range; their observations showed evidence for a relatively uniform surface. Here, we report disk-resolved observations of Ceres with SINFONI (ESO VLT) in the 1.17-1.32 {\mu}m and 1.45-2.35 {\mu}m wavelength ranges. The observations were made under excellent seeing conditions (0.6"), allowing us to reach a spatial resolution of ~75 km on Ceres' surface. We do not find any spectral variation above a 3% level, suggesting a homogeneous surface at our spatial resolution. Slight variations (about 2%) of the spectral slope are detected, geographically correlated with the albedo markings reported from the analysis of the HST and Keck disk-resolved images of Ceres (Li et al., 2006, Icarus 182, 143; Carry et al., 2008, A&A 478, 235). Given the lack of constraints on the surface composition of Ceres, however, we cannot assert the causes of these variations., Comment: 8 pages, 5 figures, 2 tables, accepted for publication in Icarus
- Published
- 2011
- Full Text
- View/download PDF
45. The Canada-France Ecliptic Plane Survey - Full Data Release: The orbital structure of the Kuiper belt
- Author
-
Petit, Jean-Marc, Kavelaars, J. John, Gladman, Brett J., Jones, R. Lynne, Parker, Joel Wm., Van Laerhoven, Christa, Nicholson, Phil, Mars, Gilbert, Rousselot, Philippe., Mousis, Olivier, Marsden, Brian, Bieryla, Allyson, Taylor, Matthew, Ashby, Matthew L. N., Benavidez, Paula, Bagatin, Adriano Campo, and Bernabeu, Guillermo
- Subjects
Astrophysics - Earth and Planetary Astrophysics - Abstract
We report the orbital distribution of the trans-neptunian objects (TNOs) discovered during the Canada-France Ecliptic Plane Survey, whose discovery phase ran from early 2003 until early 2007. The follow-up observations started just after the first discoveries and extended until late 2009. We obtained characterized observations of 321 sq.deg. of sky to depths in the range g ~ 23.5--24.4 AB mag. We provide a database of 169 TNOs with high-precision dynamical classification and known discovery efficiency. Using this database, we find that the classical belt is a complex region with sub-structures that go beyond the usual splitting of inner (interior to 3:2 mean-motion resonance [MMR]), outer (exterior to 2:1 MMR), and main (in between). The main classical belt (a=40--47 AU) needs to be modeled with at least three components: the `hot' component with a wide inclination distribution and two `cold' components (stirred and kernel) with much narrower inclination distributions. The hot component must have a significantly shallower absolute magnitude (Hg) distribution than the other two components. With 95% confidence, there are 8000+1800-1600 objects in the main belt with Hg <= 8.0, of which 50% are from the hot component, 40% from the stirred component and 10% from the kernel; the hot component's fraction drops rapidly with increasing Hg. Because of this, the apparent population fractions depend on the depth and ecliptic latitude of a trans-neptunian survey. The stirred and kernel components are limited to only a portion of the main belt, while we find that the hot component is consistent with a smooth extension throughout the inner, main and outer regions of the classical belt; the inner and outer belts are consistent with containing only hot-component objects. The Hg <= 8.0 TNO population estimates are 400 for the inner belt and 10,000 for the outer belt within a factor of two., Comment: 59 pages, 9 figures, 7 tables
- Published
- 2011
- Full Text
- View/download PDF
46. Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients.
- Author
-
Bruzzoni-Giovanelli, Heriberto, Zouali, Habib, Sahbatou, Mourad, Maneglier, Benjamin, Cayuela, Jean-Michel, Rebollo, Angelita, Marin, Gustavo H., Geromin, Daniela, Tomczak, Carole, Alberdi, Antonio, Deleuze, Jean-Francois, and Rousselot, Philippe
- Subjects
CHRONIC myeloid leukemia ,IMATINIB ,GENETIC polymorphisms ,GENETIC variation ,PROTEIN-tyrosine kinase inhibitors ,CELL adhesion ,RNA splicing - Abstract
The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial, we demonstrated that therapeutic drug monitoring (TDM) is able to improve the molecular response of CP-CML patients treated with imatinib. Here, we analyzed the constitutional exomes and RNAseq data of these patients. We performed an association analysis between the constitutional genetic variants of the patients and their ima[C]min, measured after 12 weeks of treatment with 400 mg once daily. Using linear regression, we identified 50 SNPs that showed excess heterozygosity depending on the ima[C]min. Ten SNPs were from non-coding sequences, and among the 40 remaining, 30 (from 25 genes) could be split into two categories. The first group of 16 SNPs concerns genes encoding extracellular matrix, cell junction, and membrane proteins. Coincidentally, cell adhesion proteins were also identified by RNA-seq as being overexpressed in patients with high ima[C]min. The other group of 14 SNPs were from genes encoding proteins involved in transcription/translation. Although most of the SNPs are intronic variants (28), we also identified missense (3), synonymous (4), 5′/3′ (2), splicing (1), and upstream (4) variants. A haplotype analysis of four genes showed a significant association with high ima[C]min. None of the SNPs were significantly associated with the response. In conclusion, we identified a number of ima[C]min-associated SNPs, most of which correspond to genes encoding proteins that could play a role in the diffusion and transit of imatinib through membranes or epithelial barriers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Hémophilie A acquise, le traitement par emicizumab peut relayer les agents by-passants : à propos de deux cas et une revue de la littérature.
- Author
-
Launois, Amélie, Martin-Toutain, Isabelle, Devaux, Floriane, Lambert, Juliette, Longval, Thomas, Merabet, Fatiha, Jaidi, Rym, Le Dore, Sophie, Ferre, Emmanuelle, Rousselot, Philippe, De Raucourt, Emmanuelle, and Flaujac, Claire
- Published
- 2024
- Full Text
- View/download PDF
48. Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
- Author
-
Cabannes-Hamy, Aurelie, primary, Courtois, Lucien, additional, Balsat, Marie, additional, Simonin, Mathieu, additional, Huguet, Françoise, additional, Escoffre-Barbe, Martine, additional, Pasquier, Florence, additional, Bonmati, Caroline, additional, Turlure, Pascal, additional, Cluzeau, Thomas, additional, Lebon, Delphine, additional, Gehlkopf, Eve, additional, Brissot, Eolia, additional, Decroocq, Justine, additional, Chevallier, Patrice, additional, Chantepie, Sylvain, additional, Cacheux, Victoria, additional, Maury, Sebastien, additional, Chebrek, Safia, additional, Leguay, Thibaut, additional, Fort, Melody, additional, Mauz, Natacha, additional, Lamarque, Mathlide, additional, Mathilde, Hunault-Berger, additional, Wickenhauser, Stefan, additional, Frayfer, Jamilé, additional, Banos, Anne, additional, Tavernier, Emmanuelle, additional, Caillot, Denis, additional, Ronchetti, Anne Marie, additional, Berthon, Celine, additional, Lengline, Etienne, additional, Lhéritier, Véronique, additional, Dombret, Hervé, additional, Marçais, Ambroise, additional, Pinton, Antoine, additional, Andrieu, Guillaume P, additional, Boissel, Nicolas, additional, Lhermitte, Ludovic, additional, Asnafi, Vahid, additional, and Rousselot, Philippe, additional
- Published
- 2023
- Full Text
- View/download PDF
49. CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial
- Author
-
Deininger, Michael, Apperley, Jane, Arthur, Christopher Kevin, Chuah, Charles, Hochhaus, Andreas, de Lavallade, Hugues, Lipton, Jeffrey, Lomaia, Elza, McCloskey, James, Maness, Lori, Mauro, Michael, Moraghi, Beatriz, Pavlovsky, Carolina, Rosti, Gianantonio, Rousselot, Philippe, Sutton, Maria Undurraga, Ren, Xiaowei, Vorog, Alexander, and Cortes, Jorge
- Published
- 2022
- Full Text
- View/download PDF
50. CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials
- Author
-
Apperley, Jane, Kantarjian, Hagop, Deininger, Michael, Abruzzese, Elisabetta, Cortes, Jorge, Chuah, Charles, DeAngelo, Daniel J., DiPersio, John, Hochhaus, Andreas, Lipton, Jeffrey H., Nicolini, Frank, Pinilla-Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Rousselot, Philippe, Mauro, Michael, Shah, Neil, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Jabbour, Elias
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.